These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 27891572)

  • 1. Safety concerns and risk management of multiple sclerosis therapies.
    Soelberg Sorensen P
    Acta Neurol Scand; 2017 Sep; 136(3):168-186. PubMed ID: 27891572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
    [No Abstract]   [Full Text] [Related]  

  • 8. New management algorithms in multiple sclerosis.
    Sorensen PS
    Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of relapsing-remitting multiple sclerosis.
    Tanasescu R; Ionete C; Chou IJ; Constantinescu CS
    Biomed J; 2014; 37(2):41-9. PubMed ID: 24732658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl fumarate for relapsing-remitting multiple sclerosis.
    Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siponimod (Mayzent)--a new drug for multiple sclerosis.
    Med Lett Drugs Ther; 2019 May; 61(1571):70-72. PubMed ID: 31169805
    [No Abstract]   [Full Text] [Related]  

  • 12. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on disease-modifying treatments for multiple sclerosis.
    Carrithers MD
    Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
    Eckstein C; Bhatti MT
    Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
    Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
    Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.
    Rommer PS; Zettl UK; Kieseier B; Hartung HP; Menge T; Frohman E; Greenberg BM; Hemmer B; Stüve O
    Clin Exp Immunol; 2014 Mar; 175(3):397-407. PubMed ID: 24102425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current immunotherapy of multiple sclerosis].
    Paul F; Ruprecht K
    Nervenarzt; 2015 Aug; 86(8):1031-42; quiz 1043-4. PubMed ID: 26253589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.